<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PONE-D-11-18925</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0032695</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Immunity</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Chemistry</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Mathematics</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Clinical immunology</subject>
            <subj-group>
              <subject>Immunity</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Clinical research design</subject>
          </subj-group>
          <subj-group>
            <subject>Oncology</subject>
            <subj-group>
              <subject>Cancers and neoplasms</subject>
              <subj-group>
                <subject>Lung and intrathoracic tumors</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Immunology</subject>
          <subject>Chemistry</subject>
          <subject>Oncology</subject>
          <subject>Mathematics</subject>
        </subj-group>
      </article-categories><title-group><article-title>Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of 12 Randomized Controlled Trials</article-title><alt-title alt-title-type="running-head">Meta-Analysis of Immunotherapy for Advanced NSCLC</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Wang</surname>
            <given-names>Juan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Zou</surname>
            <given-names>Ze-Hong</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Xia</surname>
            <given-names>Hong-Lin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>He</surname>
            <given-names>Jian-Xing</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Zhong</surname>
            <given-names>Nan-Shan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Tao</surname>
            <given-names>Ai-Lin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">          <addr-line>Guangzhou Municipal Key Laboratory of Allergy and Clinical Immunology, Allergy Research Branch of the State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Chiyu</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Jiangsu University, China</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">taoailin@gzhmc.edu.cn</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: ALT JW NSZ JXH. Performed the experiments: JW ZHZ HLX. Analyzed the data: JW HLX ZHZ JXH NSZ ALT. Contributed reagents/materials/analysis tools: JW HLX ZHZ. Wrote the paper: JW ZHZ ALT. Final approval of manuscript: JW HLX ZHZ JXH NSZ ALT. Administrative support: ZHZ JXH NSZ ALT.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <year>2012</year>
      </pub-date><pub-date pub-type="epub">
        <day>5</day>
        <month>3</month>
        <year>2012</year>
      </pub-date><volume>7</volume><issue>3</issue><elocation-id>e32695</elocation-id><history>
        <date date-type="received">
          <day>21</day>
          <month>9</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>1</month>
          <year>2012</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2012</copyright-year><copyright-holder>Wang et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <sec>
          <title>Background</title>
          <p>Lung cancer is one of the leading causes of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Immunotherapy has yielded no consistent benefit to date for those patients. Assessing the objective efficacy and safety of immunotherapy for advanced NSCLC patients will help to instruct the future development of immunotherapeutic drugs.</p>
        </sec>
        <sec>
          <title>Methodology and Principal Findings</title>
          <p>We performed a meta-analysis of 12 randomized controlled trials including 3134 patients (1570 patients in the immunotherapy group and 1564 patients in the control group) with histologically confirmed stage IIIA, IIIB, or IV NSCLC. The analysis was executed with efficacy end points regarding overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and total effective rate. Overall unstratified OS, PFS, PR, and total effective rate were significantly improved in advanced NSCLC patients in the immunotherapy group (<italic>P</italic> = 0.0007, 0.0004, 0.002, 0.003, respectively), whereas CR was not improved (<italic>P</italic> = 0.97). Subgroup analysis showed that monoclonal antibody (mAb) immunotherapy significantly improved the PFS, PR, and total effective rate and showed a trend of improving OS of advanced NSCLC patients compared with the control group, with one kind of adverse event being significantly dominant. Compared with the control group, the vaccine subgroup showed no significant difference with regard to serious adverse events, whereas cytokine immunotherapy significantly induced three kinds of serious adverse events.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Immunotherapy works efficiently on advanced NSCLC patients. Of several immunotherapies, mAb therapy may be a potential immunotherapy for advanced NSCLC patients, and become a standard complementary therapeutic approach in the future if the issues concerning toxicity and allergenicity of mAbs have been overcome.</p>
        </sec>
      </abstract><funding-group><funding-statement>This work was supported by Key Program from Guangdong Provincial Natural Science Foundation (8251018201000002) and Programs from National Natural Science Foundation of China (No.30640033, No.30771240). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="12"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>In 2008, lung cancer was the most commonly diagnosed cancer, as well as the leading cause of cancer death in males worldwide. Among females, it was the fourth most commonly diagnosed cancer and the second leading cause of cancer death <xref ref-type="bibr" rid="pone.0032695-Jemal1">[1]</xref>. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers <xref ref-type="bibr" rid="pone.0032695-Gridelli1">[2]</xref>.</p>
      <p>Despite recent advances in surgery, irradiation, and chemotherapy, the prognosis of patients with lung cancer is still poor <xref ref-type="bibr" rid="pone.0032695-Yasumoto1">[3]</xref>. About 50% of patients recur after surgery, and less than 25% of patients respond to systemic chemotherapy <xref ref-type="bibr" rid="pone.0032695-Kakimi1">[4]</xref>. For patients with unresectable stage III NSCL, chemotherapy has limited benefits <xref ref-type="bibr" rid="pone.0032695-Palmer1">[5]</xref>, <xref ref-type="bibr" rid="pone.0032695-Gadgeel1">[6]</xref>. For advanced NSCLC patients, chemotherapy induces significant safety issues. For example, in one study including 1371 patients, of 58% patients who received chemotherapy, 35% had adverse events (AEs) and more than 12% had serious AEs <xref ref-type="bibr" rid="pone.0032695-Chrischilles1">[7]</xref>.</p>
      <p>Thus, it urgently requires safer and more effective treatments for lung cancer to improve the quality and duration of life. Immunotherapy seems an attractive therapeutic approach for lung cancer due to its theoretical specificity and potential for long-term disease control <xref ref-type="bibr" rid="pone.0032695-Holt1">[8]</xref>. At present, the main strategies of immunotherapy for advanced NSCLC include vaccines, cytokines, and monoclonal antibodies (mAbs). Vaccine immunotherapy prompts the immune system to kill cancer cells <xref ref-type="bibr" rid="pone.0032695-Raez1">[9]</xref>, immunotherapy with cytokines counteracts the immunodeficiency state caused by the tumor, and monoclonal antibodies (mAbs) target specific tumor antigens and induce immune response against cancer <xref ref-type="bibr" rid="pone.0032695-Morgensztern1">[10]</xref>. However, immunotherapy trials for lung cancer have yielded no consistent benefit to date in humans because tumor cells can escape the immune attack and develop different resistance mechanisms <xref ref-type="bibr" rid="pone.0032695-Raez1">[9]</xref>. Combination of immunotherapy with surgery, chemotherapy, or radiotherapy may be valuable in NSCLC patients; nevertheless the model of multi-modality in NSCLC is still being debated.</p>
      <p>Meta-analysis based on data from pooled patient samples provides an avenue for evaluating the efficacy and side effects of immunotherapy for advanced NSCLC patients. In this study, we used a meta-analysis to evaluate the efficacy and safety of the immunotherapies (including chemo-immunotherapy) on advanced NSCLC patients.</p>
    </sec>
    <sec id="s2" sec-type="methods">
      <title>Methods</title>
      <sec id="s2a">
        <title>Literature Search Strategy</title>
        <p>This meta-analysis adhered to the relevant criteria of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement <xref ref-type="bibr" rid="pone.0032695-Moher1">[11]</xref>. A search was conducted on Highwire (PubMed included) for original studies published between January 1980 and April 2011 on immunotherapy for NSCLC, using the following keywords: “immunotherapy” OR “immunotherapeutic” AND “non-small-cell lung cancer” OR “NSCLC.” Review papers were also examined for published results. By carefully examining the body of each publication and the names of all authors, we avoided duplications of data. When such duplications were identified, the latest version was included in this study. The search strategy used is illustrated in <xref ref-type="fig" rid="pone-0032695-g001">Figure 1</xref>.</p>
        <fig id="pone-0032695-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0032695.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Study Flowchart.</title>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.g001" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2b">
        <title>Selection Criteria</title>
        <p>The selection criteria were as follows: (1) studies were in the English language and were limited to human trials; (2) data regarding tumors without specific documentation of lung origin were excluded; (3) case studies, review articles, and studies involving fewer than three patients were excluded; and (4) studies adopting randomized controlled trials to compare immunotherapy versus control therapy and including patients at stage IIIA, IIIB, or IV were included.</p>
      </sec>
      <sec id="s2c">
        <title>Data Extraction and Quality Assessment</title>
        <p>Three reviewers, JW, HLX and ALT, independently selected the trials and performed the data extraction. Discrepancies were resolved by discussion among the reviewers. The clinical outcomes used to evaluate efficacy and safety of immunotherapy in advanced NSCLC were overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and the total effective rate (CR + PR). OS was defined as the period from the randomization date to the date of death. PFS was defined as the period from the randomization date to the date when disease progression (or death) was observed. We assessed the objective cancer response as total effective rate, CR, and PR.</p>
        <p>For the meta-analysis of immunotherapy for NSCLC, the overall quality of each study was assessed in accordance with the Jadad Scale <xref ref-type="bibr" rid="pone.0032695-Jadad1">[12]</xref>. A grading scheme (a, b, and c) was used to classify four main criteria: (1) quality of randomization; (2) quality of allocation concealment; (3) quality of blinding; and (4) quality of the description of withdrawals and dropouts <xref ref-type="bibr" rid="pone.0032695-Rao1">[13]</xref>. The grades indicate: (a) adequate, with appropriate procedures; (b) unclear, inappropriate description of methods; and (c) inadequate procedures, methods, or information <xref ref-type="bibr" rid="pone.0032695-Clark1">[14]</xref>. Based on these four criteria, each study cited can be categorized as follows: A. studies have a low risk of bias and were scored as grade a for all items; B. studies have a moderate risk of bias with one or more grades of b; and C. studies have a high risk of bias with one or more grades of c.</p>
      </sec>
      <sec id="s2d">
        <title>Assessment of Safety</title>
        <p>For the trials included in this study, different grades of toxicity and serious adverse events (SAEs) were observed during the follow-up periods. An event that was fatal, life-threatening, required hospitalization or prolonged existing hospitalization, or caused a persistent or significant disability/incapacity was defined as an SAE <xref ref-type="bibr" rid="pone.0032695-Wu1">[15]</xref>. AEs were graded using the National Cancer Institute Common Toxicity Criteria, version 2.0, except AEs reported by Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, which were graded using WHO criteria.</p>
        <p>The included trials were classified into three subgroups (cytokines, mAbs, and vaccines) based on the three categories of immunotherapeutic drugs administered for advanced NSCLC. Subgroup analysis of the SAEs was performed using Peto odds ratio <xref ref-type="bibr" rid="pone.0032695-Bradburn1">[17]</xref> to assess the significance of differences between the experimental arm and its control arm in each subgroup.</p>
      </sec>
      <sec id="s2e">
        <title>Statistical Analysis</title>
        <p>Statistical analysis was carried out using Review Manager (version 5.0) provided by The Cochrane Collaboration. Dichotomous data are presented as hazard ratios (HR) and continuous outcomes as weighted mean differences, both with the 95% confidence interval (CI). HR and CI were calculated according to Cox proportional hazards modeling <xref ref-type="bibr" rid="pone.0032695-Cox1">[18]</xref>. An HR&lt;1 means a lower rate of events in the maintenance arm <xref ref-type="bibr" rid="pone.0032695-Thatcher1">[19]</xref>. The overall effect was tested using <italic>Z</italic> scores, with significance set at <italic>P</italic>&lt;0.05. Meta-analysis was performed using random-effect or fixed-effect methods, depending on the presence or absence of significant heterogeneity <xref ref-type="bibr" rid="pone.0032695-Higgins1">[20]</xref>. Statistical heterogeneity between trials was evaluated by the χ<sup>2</sup> and <italic>I</italic><sup>2</sup> tests, with significance set at <italic>P</italic>&lt;0.10. When heterogeneity was confirmed, the random-effect method was used. In the absence of statistically significant heterogeneity, the fixed-effect method was used to combine the results. Sensitivity analysis was conducted with alternative exclusion of trials by Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref> or Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>, two trials that did not apply chemotherapy in both the experimental and control arms.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Quantity of Evidence</title>
        <p>A total of 287 studies were identified by the searches. By scanning titles and abstracts, redundant publications, reviews, meeting abstracts, and case reports were excluded. After referring to full texts, we removed 275 studies that did not meet the selection criteria (<xref ref-type="fig" rid="pone-0032695-g001">Figure 1</xref>). As a result, 12 studies <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>–<xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref> that included a total of 3134 patients were selected for meta-analysis.</p>
        <p>The details of the 12 trials are listed in <xref ref-type="table" rid="pone-0032695-t001">Table 1</xref>. Although six studies did not describe OS <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref> or PFS <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>, <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref>, <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref> and four studies did not provide the number of patients in CR and/or PR rates <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>, <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref>, <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref>, all 12 studies were open-labeled and randomized. They mentioned the concealment of allocation clearly in the randomization process, and provided the number of patients who withdrew from the trials. Therefore, the 12 studies provided adequate information and were thus considered to be A. studies in this meta-analysis (<xref ref-type="table" rid="pone-0032695-t002">Table 2</xref>).</p>
        <table-wrap id="pone-0032695-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t001</object-id><label>Table 1</label><caption>
            <title>Detailed data of the 12 trials included in the meta-analysis.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Source [Reference]</td>
                <td align="left" colspan="1" rowspan="1">Trial phase</td>
                <td align="left" colspan="1" rowspan="1">Stage of patients</td>
                <td align="left" colspan="1" rowspan="1">Follow-up (years)</td>
                <td align="left" colspan="1" rowspan="1">Study groups</td>
                <td align="left" colspan="1" rowspan="1">Treatment design</td>
                <td align="left" colspan="1" rowspan="1">Dosage</td>
                <td align="left" colspan="1" rowspan="1">No. of patients (<italic>N</italic> = 3134)</td>
                <td align="left" colspan="5" rowspan="1">No. of events/No. of subjects</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">OS</td>
                <td align="left" colspan="1" rowspan="1">PFS</td>
                <td align="left" colspan="1" rowspan="1">CR</td>
                <td align="left" colspan="1" rowspan="1">PR</td>
                <td align="left" colspan="1" rowspan="1">TER</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase II</td>
                <td align="left" colspan="1" rowspan="1">IIIA/IIIB</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">MLT + low-dose rIL-2</td>
                <td align="left" colspan="1" rowspan="1">3×106 IU/day/40 mg/day</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">27</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">7</td>
                <td align="left" colspan="1" rowspan="1">7</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">CE</td>
                <td align="left" colspan="1" rowspan="1">C (20 mg/m2), E (100 mg/m2)</td>
                <td align="left" colspan="1" rowspan="1">31</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">6</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase II</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">EGF vaccinations</td>
                <td align="left" colspan="1" rowspan="1">50 µg</td>
                <td align="left" colspan="1" rowspan="1">40</td>
                <td align="left" colspan="1" rowspan="1">35</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">7</td>
                <td align="left" colspan="1" rowspan="1">7</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">BSC</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">40</td>
                <td align="left" colspan="1" rowspan="1">38</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">9</td>
                <td align="left" colspan="1" rowspan="1">11</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase IIB</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">BSC + L-BLP25</td>
                <td align="left" colspan="1" rowspan="1">1000 µg/No</td>
                <td align="left" colspan="1" rowspan="1">88</td>
                <td align="left" colspan="1" rowspan="1">61</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">49</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">49</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">BSC</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">83</td>
                <td align="left" colspan="1" rowspan="1">69</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">45</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">45</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Gatzemeier et al. <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase II</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">1.7</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">TGC</td>
                <td align="left" colspan="1" rowspan="1">T (4 mg/kg)/G (1250 mg/m<sup>2</sup>), C (75 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">51</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">45</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">16</td>
                <td align="left" colspan="1" rowspan="1">18</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">GC</td>
                <td align="left" colspan="1" rowspan="1">G (1250 mg/m<sup>2</sup>), C (75 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">50</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">42</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">20</td>
                <td align="left" colspan="1" rowspan="1">21</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Lasalvia-Prisco et al. <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase II</td>
                <td align="left" colspan="1" rowspan="1">IV</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">GM-CSF + Cyclophosphamide</td>
                <td align="left" colspan="1" rowspan="1">300 mg/m<sup>2</sup>/300 µg SC</td>
                <td align="left" colspan="1" rowspan="1">44</td>
                <td align="left" colspan="1" rowspan="1">21</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">14</td>
                <td align="left" colspan="1" rowspan="1">14</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">CHT</td>
                <td align="left" colspan="1" rowspan="1">D (100 mg/m<sup>2</sup>), C (80 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">44</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">15</td>
                <td align="left" colspan="1" rowspan="1">16</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Lynch et al. <xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase III</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">TC + Cetuximab</td>
                <td align="left" colspan="1" rowspan="1">400 mg/m<sup>2</sup>/T (225 mg/m<sup>2</sup>), C (6, 30-min IV)</td>
                <td align="left" colspan="1" rowspan="1">338</td>
                <td align="left" colspan="1" rowspan="1">277</td>
                <td align="left" colspan="1" rowspan="1">284</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">87</td>
                <td align="left" colspan="1" rowspan="1">87</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">TC</td>
                <td align="left" colspan="1" rowspan="1">T (225 mg/m<sup>2</sup>), C (6, 30-min IV)</td>
                <td align="left" colspan="1" rowspan="1">338</td>
                <td align="left" colspan="1" rowspan="1">287</td>
                <td align="left" colspan="1" rowspan="1">263</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">57</td>
                <td align="left" colspan="1" rowspan="1">58</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">O'Brien et al. <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase III</td>
                <td align="left" colspan="1" rowspan="1">IIIA/IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">MVP + SRL172</td>
                <td align="left" colspan="1" rowspan="1">M (8–10 mg/m<sup>2</sup>), V (6 mg/m<sup>2</sup>), C (50–120 mg/m<sup>2</sup>)/0.1 ml</td>
                <td align="left" colspan="1" rowspan="1">210</td>
                <td align="left" colspan="1" rowspan="1">197</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">MVP</td>
                <td align="left" colspan="1" rowspan="1">M (8–10 mg/m<sup>2</sup>), V (6 mg/m<sup>2</sup>), C (50–120 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">209</td>
                <td align="left" colspan="1" rowspan="1">201</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Pirker et al. <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase III</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">2.5</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">VC + Cetuximab</td>
                <td align="left" colspan="1" rowspan="1">V (25 mg/m<sup>2</sup>), C (80 mg/m<sup>2</sup>)/400 mg/m<sup>2</sup></td>
                <td align="left" colspan="1" rowspan="1">557</td>
                <td align="left" colspan="1" rowspan="1">468</td>
                <td align="left" colspan="1" rowspan="1">446</td>
                <td align="left" colspan="1" rowspan="1">9</td>
                <td align="left" colspan="1" rowspan="1">194</td>
                <td align="left" colspan="1" rowspan="1">203</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">VC</td>
                <td align="left" colspan="1" rowspan="1">V (25 mg/m<sup>2</sup>), C (80 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">568</td>
                <td align="left" colspan="1" rowspan="1">494</td>
                <td align="left" colspan="1" rowspan="1">408</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">160</td>
                <td align="left" colspan="1" rowspan="1">166</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Ridolfi et al. <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase III</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">GC + IL-2</td>
                <td align="left" colspan="1" rowspan="1">G (1000 mg/m<sup>2</sup>), C (100 mg/m<sup>2</sup>)/3,000,000 IU/die</td>
                <td align="left" colspan="1" rowspan="1">127</td>
                <td align="left" colspan="1" rowspan="1">93</td>
                <td align="left" colspan="1" rowspan="1">111</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">18</td>
                <td align="left" colspan="1" rowspan="1">18</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">GC</td>
                <td align="left" colspan="1" rowspan="1">G (1000 mg/m<sup>2</sup>), C (100 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">114</td>
                <td align="left" colspan="1" rowspan="1">85</td>
                <td align="left" colspan="1" rowspan="1">99</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">12</td>
                <td align="left" colspan="1" rowspan="1">13</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Rosell et al. <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase II</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">VC + Cetuximab</td>
                <td align="left" colspan="1" rowspan="1">V (25 mg/m<sup>2</sup>), C (80 mg/m<sup>2</sup>)/400 mg/m<sup>2</sup></td>
                <td align="left" colspan="1" rowspan="1">43</td>
                <td align="left" colspan="1" rowspan="1">36</td>
                <td align="left" colspan="1" rowspan="1">28</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">15</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">VC</td>
                <td align="left" colspan="1" rowspan="1">V (25 mg/m<sup>2</sup>), C (80 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">43</td>
                <td align="left" colspan="1" rowspan="1">40</td>
                <td align="left" colspan="1" rowspan="1">28</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">12</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Wu et al. <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase II</td>
                <td align="left" colspan="1" rowspan="1">IIIA/IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">2.5</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">TP + CIK</td>
                <td align="left" colspan="1" rowspan="1">D (75 mg/m<sup>2</sup>), C (25 mg/m<sup>2</sup>)/1.0×10<sup>9</sup> cells</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">23</td>
                <td align="left" colspan="1" rowspan="1">27</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">13</td>
                <td align="left" colspan="1" rowspan="1">13</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">TP</td>
                <td align="left" colspan="1" rowspan="1">D (75 mg/m<sup>2</sup>), C (25 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">30</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">13</td>
                <td align="left" colspan="1" rowspan="1">13</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Zhong et al. <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
                <td align="left" colspan="1" rowspan="1">Phase I/II</td>
                <td align="left" colspan="1" rowspan="1">IIIB/IV</td>
                <td align="left" colspan="1" rowspan="1">∼5</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">NP + peptide-pulsed autologous dendritic cells and CIK cells</td>
                <td align="left" colspan="1" rowspan="1">V (25 mg/m<sup>2</sup>), C (75 mg/m<sup>2</sup>)/Repeated at 30-day</td>
                <td align="left" colspan="1" rowspan="1">14</td>
                <td align="left" colspan="1" rowspan="1">12</td>
                <td align="left" colspan="1" rowspan="1">13</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">NP</td>
                <td align="left" colspan="1" rowspan="1">V (25 mg/m<sup>2</sup>), C (75 mg/m<sup>2</sup>)</td>
                <td align="left" colspan="1" rowspan="1">14</td>
                <td align="left" colspan="1" rowspan="1">13</td>
                <td align="left" colspan="1" rowspan="1">14</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
                <td align="left" colspan="1" rowspan="1">No</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p><bold>Note:</bold> 3134 patients were included in the meta-analysis, with 1570 assigned to the experimental groups (Exp) treated with immunotherapy and 1564 in the control groups (Con).</p>
            </fn>
            <fn id="nt102">
              <label/>
              <p><bold>Abbreviations:</bold> CR, complete response rate; OS, overall survival; PFS, progression-free survival; PR, partial response rate; TER, total effective rate, which is equal to CR plus PR; No, no detailed data; BSC, best supportive care without drug regimen; C, cisplatin; CE: cisplatin + etoposide.; CHT, chemotherapy (docetaxel + cisplatin); CHIMT, CHT + an immunomodulatory adjuvant system; CIK, cytokine-induced killer biotherapy; D, docetaxel; EGF, epidermal growth factor; GC: gemcitabine-cisplatin; GM-CSF, granulocyte macrophage-colony stimulating factor; L-BLP25, BLP25 liposome vaccine; MLT, melatonin; MVP, mitomycin C + vinblastine + cisplatin; NP, vinorelbine-platinum; rIL-2, recombinant interleukin 2; SRL172, killed <italic>Mycobacterium vaccae</italic>; TC, taxane + cisplatin; TCG: trastuzumab + gemcitabine-cisplatin; TP, docetaxel + cisplatin; V, vinorelbine.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <table-wrap id="pone-0032695-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t002</object-id><label>Table 2</label><caption>
            <title>Jadad Scale for the 12 randomized controlled studies.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t002" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Author [Reference]</td>
                <td align="left" colspan="1" rowspan="1">Randomization (grades)</td>
                <td align="left" colspan="1" rowspan="1">Allocation concealment (grades)</td>
                <td align="left" colspan="1" rowspan="1">Blinding(grades)</td>
                <td align="left" colspan="1" rowspan="1">Description of withdrawals (grades)</td>
                <td align="left" colspan="1" rowspan="1">Category</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Gatzemeier et al. <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Lasalvia-Prisco et al. <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Lynch et al. <xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">O'Brien et al. <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Pirker et al. <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Ridolfi et al. <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Rosell et al. <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Wu et al. <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Zhong et al. <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">a</td>
                <td align="left" colspan="1" rowspan="1">A</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt103">
              <label>a</label>
              <p>: adequate, with correct procedures;</p>
            </fn>
            <fn id="nt104">
              <label>b</label>
              <p>: unclear, without a description of methods; and.</p>
            </fn>
            <fn id="nt105">
              <label>c</label>
              <p>: inadequate procedures, methods, or information. A studies have a low risk of bias and were scored as grade a for all items.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s3b">
        <title>Meta-Analysis of Immunotherapy for Advanced NSCLC</title>
        <p>The analysis results of OS are shown in <xref ref-type="fig" rid="pone-0032695-g002">Figure 2</xref>. No significant heterogeneity was detected for total unstratified immunotherapy or the three subgroups defined by immunotherapeutic categories (<xref ref-type="fig" rid="pone-0032695-g002">Figure 2</xref>). A fixed-effect model was therefore used for OS analysis. The overall analysis showed that immunotherapy significantly increased OS at the end of follow-up compared with the control group (<italic>Z</italic> = 3.39, <italic>P</italic> = 0.0007). However, subgroup patients did not consistently gain an OS benefit from the various immunotherapies. The vaccine group behaved the same as total unstratified immunotherapy and improved OS significantly (HR = 0.94, 95% CI = 0.89–0.98; <italic>Z = </italic>2.59, <italic>P</italic> = 0.009), whereas the cytokine group (HR = 0.92; 95% CI = 0.83–1.01; <italic>Z = </italic>1.75, <italic>P</italic> = 0.08) and mAb group (HR = 0.96, 95% CI = 0.93–1.00; <italic>Z = </italic>1.96, <italic>P</italic> = 0.05) did not produce any significant improvement in OS compared with their corresponding control groups.</p>
        <fig id="pone-0032695-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0032695.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Forest plot of comparison of overall survival of 11 included studies (Stage IIIA, IIIB, or IV NSCLC).</title>
            <p><italic>P</italic> values are from P-for-effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of deaths in the trials. CI, confidence interval; HR, hazard ratio.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.g002" xlink:type="simple"/>
        </fig>
        <p>Because the vaccine trials did not present PFS data, only the mAb and cytokine groups were subjected to subgroup analysis. No obvious heterogeneity (χ<sup>2</sup> = 8.78, df = 6, <italic>P</italic> = 0.19; <italic>I</italic><sup>2</sup> = 32%, 95% CI = 0–71%) was detected for total unstratified immunotherapy (<xref ref-type="fig" rid="pone-0032695-g003">Figure 3</xref>). Heterogeneity was observed in both the mAb and cytokine groups, allowing the use of different models for the overall and subgroup analyses of PFS. mAbs clearly delayed the time to disease progression (HR = 1.09, 95% CI = 1.04–1.15; <italic>Z = </italic>3.75, <italic>P</italic> = 0.0002), which was consistent with overall immunotherapy (HR = 1.08, 95% CI = 1.03–1.12; <italic>Z</italic> = 3.51, <italic>P</italic> = 0.0004). However, compared with the control group, patients in cytokines group did not have a significant improvement in PFS (HR = 0.99, 95% CI = 0.92–1.07; <italic>Z</italic> = 0.24, <italic>P</italic> = 0.81).</p>
        <fig id="pone-0032695-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0032695.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Forest plot of comparison of progression-free survival of 7 included studies (Stage IIIA, IIIB, or IV NSCLC).</title>
            <p><italic>P</italic> values are from P-for-effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of PFS events in the trials. CI, confidence interval; HR, hazard ratio.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.g003" xlink:type="simple"/>
        </fig>
        <p>Because of no heterogeneity, fixed-effect models were used to analyze total effective rates and PR rates of total unstratified immunotherapy group and all subgroups (<xref ref-type="fig" rid="pone-0032695-g004">Figures 4</xref> and <xref ref-type="fig" rid="pone-0032695-g005">5</xref>). The overall analysis demonstrated that immunotherapy substantially improved both the total effective rate (HR = 1.19, 95% CI = 1.06–1.34; <italic>Z = </italic>3.01, <italic>P</italic> = 0.003) and PR rate (HR = 1.23, 95% CI = 1.08–1.40, <italic>Z = </italic>3.07, <italic>P</italic> = 0.002) compared with the control arms. mAb therapy significantly improved the total effective rate (HR = 1.27, 95% CI = 1.11–1.46, <italic>Z</italic> = 3.42, <italic>P</italic> = 0.0006) and PR rate (HR = 1.27, 95% CI = 1.10–1.46, <italic>Z</italic> = 3.32, <italic>P</italic> = 0.001), whereas cytokine and vaccine immunotherapy both generated no statistically significant improvement.</p>
        <fig id="pone-0032695-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0032695.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Forest plot of comparison of total effective rate of 10 included studies (Stage IIIA, IIIB, or IV NSCLC).</title>
            <p><italic>P</italic> values are from P-for-effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of total effective rate events in the trials. CI, confidence interval; HR, hazard ratio.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.g004" xlink:type="simple"/>
        </fig>
        <fig id="pone-0032695-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0032695.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Forest plot of comparison of partial response of 8 included studies (Stage IIIA, IIIB, or IV NSCLC).</title>
            <p><italic>P</italic> values are from P-for-effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of PR rate events in the trials. CI, confidence interval; HR, hazard ratio.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.g005" xlink:type="simple"/>
        </fig>
        <p>Fixed-effect models were also applied for the analysis of CR in the overall immunotherapy group and three subgroups. The results showed that neither total unstratified immunotherapy (HR = 1.00, 95% CI = 0.77–1.31; <italic>Z = </italic>0.03, <italic>P</italic> = 0.97) nor the immunotherapy subgroups had a significant impact on CR rate compared with their corresponding control arms (<xref ref-type="fig" rid="pone-0032695-g006">Figure 6</xref>).</p>
        <fig id="pone-0032695-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0032695.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Forest plot of comparison of complete response of 9 included trials (Stage IIIA, IIIB, or IV NSCLC).</title>
            <p><italic>P</italic> values are from P-for-effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of CR rate events in the trials. CI, confidence interval; HR, hazard ratio.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.g006" xlink:type="simple"/>
        </fig>
        <p>Because not all the efficacy parameters were reported by all the trials reviewed, sensitivity analyses were performed separately on each parameter following the alternative exclusion of the trials by Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-Higgins1">[20]</xref> or Butts et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, which did not apply chemotherapy. For the efficacy parameters analyzed, results were all the same to those found in the overall analysis of the pooled trials (<xref ref-type="table" rid="pone-0032695-t003">Table 3</xref>).</p>
        <table-wrap id="pone-0032695-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t003</object-id><label>Table 3</label><caption>
            <title>Sensitivity analysis for the outcome of studies not using chemotherapy<xref ref-type="table-fn" rid="nt106">*</xref>.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t003" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Excluded trials</td>
                <td align="left" colspan="1" rowspan="1">Efficacy items</td>
                <td align="left" colspan="1" rowspan="1">No. of randomized controlled trials subjected to sensitivity analysis [References]</td>
                <td align="left" colspan="2" rowspan="1">No. of events/Group total subjects</td>
                <td align="left" colspan="2" rowspan="1">Odds ratio</td>
                <td align="left" colspan="2" rowspan="1">Heterogeneity test</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Experimental</td>
                <td align="left" colspan="1" rowspan="1">Control</td>
                <td align="left" colspan="1" rowspan="1">Mean (95% CI)</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
                <td align="left" colspan="1" rowspan="1"><italic>I</italic><sup>2</sup> (95% CI)</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neninger Vinageras et al.<xref ref-type="table-fn" rid="nt107">a</xref></td>
                <td align="left" colspan="1" rowspan="1">Overall survival</td>
                <td align="left" colspan="1" rowspan="1">10 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>, <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref>–<xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
                <td align="left" colspan="1" rowspan="1">1215/1479</td>
                <td align="left" colspan="1" rowspan="1">1276/1474</td>
                <td align="left" colspan="1" rowspan="1">0.71 (0.58–0.87)</td>
                <td align="left" colspan="1" rowspan="1">0.001</td>
                <td align="left" colspan="1" rowspan="1">0.39</td>
                <td align="left" colspan="1" rowspan="1">6% (0–65%)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Total effective rate</td>
                <td align="left" colspan="1" rowspan="1">9 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>–<xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>–<xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">424/1306</td>
                <td align="left" colspan="1" rowspan="1">350/1301</td>
                <td align="left" colspan="1" rowspan="1">1.33 (1.12–1.58)</td>
                <td align="left" colspan="1" rowspan="1">0.001</td>
                <td align="left" colspan="1" rowspan="1">0.52</td>
                <td align="left" colspan="1" rowspan="1">0% (0–65%)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Complete response</td>
                <td align="left" colspan="1" rowspan="1">8 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>–<xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>, <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref>, <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">60/1263</td>
                <td align="left" colspan="1" rowspan="1">55/1258</td>
                <td align="left" colspan="1" rowspan="1">1.08 (0.66–1.76)</td>
                <td align="left" colspan="1" rowspan="1">0.77</td>
                <td align="left" colspan="1" rowspan="1">0.79</td>
                <td align="left" colspan="1" rowspan="1">0% (0–75%)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Partial response</td>
                <td align="left" colspan="1" rowspan="1">7 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref>–<xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>, <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref>, <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">349/1175</td>
                <td align="left" colspan="1" rowspan="1">283/1175</td>
                <td align="left" colspan="1" rowspan="1">1.35 (1.13–1.63)</td>
                <td align="left" colspan="1" rowspan="1">0.001</td>
                <td align="left" colspan="1" rowspan="1">0.42</td>
                <td align="left" colspan="1" rowspan="1">1% (0–71%)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Butts et al.<xref ref-type="table-fn" rid="nt108">b</xref></td>
                <td align="left" colspan="1" rowspan="1">Overall survival</td>
                <td align="left" colspan="1" rowspan="1">10 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref>–<xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
                <td align="left" colspan="1" rowspan="1">1189/1431</td>
                <td align="left" colspan="1" rowspan="1">1245/1431</td>
                <td align="left" colspan="1" rowspan="1">0.73 (0.59–0.90)</td>
                <td align="left" colspan="1" rowspan="1">0.004</td>
                <td align="left" colspan="1" rowspan="1">0.65</td>
                <td align="left" colspan="1" rowspan="1">0% (0–62%)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Total effective rate</td>
                <td align="left" colspan="1" rowspan="1">9 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref>–<xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>–<xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">382/1258</td>
                <td align="left" colspan="1" rowspan="1">316/1258</td>
                <td align="left" colspan="1" rowspan="1">1.32 (1.11–1.58)</td>
                <td align="left" colspan="1" rowspan="1">0.002</td>
                <td align="left" colspan="1" rowspan="1">0.43</td>
                <td align="left" colspan="1" rowspan="1">0% (0–65%)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Complete response</td>
                <td align="left" colspan="1" rowspan="1">8 <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref>–<xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>, <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref>, <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref></td>
                <td align="left" colspan="1" rowspan="1">11/1215</td>
                <td align="left" colspan="1" rowspan="1">12/1215</td>
                <td align="left" colspan="1" rowspan="1">0.92 (0.40–2.10)</td>
                <td align="left" colspan="1" rowspan="1">0.84</td>
                <td align="left" colspan="1" rowspan="1">0.61</td>
                <td align="left" colspan="1" rowspan="1">0% (0–75%)</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt106">
              <label>*</label>
              <p>Statistical heterogeneity was <italic>P</italic>&gt;0.1 for all sensitivity analyses. Sensitivity analysis was conducted according to Peto odds ratio method. CI, confidence interval.</p>
            </fn>
            <fn id="nt107">
              <label>a</label>
              <p>Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref> did not report progression-free survival.</p>
            </fn>
            <fn id="nt108">
              <label>b</label>
              <p>Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref> did not report progression-free survival and partial response.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s3c">
        <title>Safety</title>
        <p>Safety analyses were based on AEs found by the clinical and laboratory examinations in the 12 trials. The treatment-related AEs (grades ≥3) and the immunotherapy efficacy for stage IIIA, IIIB, or IV NSCLC patients are summarized in <xref ref-type="table" rid="pone-0032695-t004">Tables 4</xref>, <xref ref-type="table" rid="pone-0032695-t005">5</xref>, <xref ref-type="table" rid="pone-0032695-t006">6</xref> and <xref ref-type="table" rid="pone-0032695-t007">7</xref>. Among the 12 trials reviewed, four cytokine and vaccine trials <xref ref-type="bibr" rid="pone.0032695-Higgins1">[20]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref>, <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref> did not provide detailed data or presented somewhat contradictory results on safety. Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref> and Wu et al. <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref> did not observe serious treatment-related AEs (grade ≥3), whereas Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref> and Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref> reported serious AEs with a significantly less frequently in immunotherapy groups versus control groups. Because various AEs occurred in the other eight trials (<xref ref-type="table" rid="pone-0032695-t004">Table 4</xref>), an overall analysis of safety was conducted. Compared with the control groups, four kinds of serious AEs occurred more frequently in immunotherapy groups: diarrhea, hypomagnesemia, leucopenia, and thrombocytopenia. Six other kinds of AEs occurred equally in the immunotherapy and control groups (<xref ref-type="table" rid="pone-0032695-t005">Tables 5</xref>, <xref ref-type="table" rid="pone-0032695-t006">6</xref> and <xref ref-type="table" rid="pone-0032695-t007">7</xref>). The results indicated that immunotherapy or the combination of immunotherapy with other therapy could lead to different grades of AEs or toxic reactions in patients with advanced NSCLC, and there were fewer episodes of AEs in immunotherapy groups than in non-immunotherapy groups. Diarrhea, hypomagnesemia, and leucopenia occurred more frequently in patients receiving cytokine immunotherapy than in the control group, whereas thrombocytopenia occurred more frequently in the mAb subgroup. Patients receiving vaccine therapy experienced serious AEs with a similar frequency to the control group. With regard to less serious AEs, episodes of non-infectious fever were significantly more frequent in patients receiving immunotherapy than in those receiving chemotherapy in two trials (<italic>P</italic>&lt;0.05, <italic>P</italic> = 0.02, respectively) <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref>.</p>
        <table-wrap id="pone-0032695-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t004</object-id><label>Table 4</label><caption>
            <title>Adverse events (grades ≥3) in advanced NSCLC patients<xref ref-type="table-fn" rid="nt109">*</xref>.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t004-4" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t004" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Adverse events</td>
                <td align="left" colspan="2" rowspan="1">Gatzemeier et al. <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref></td>
                <td align="left" colspan="2" rowspan="1">Lasalvia-Prisco et al. <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref></td>
                <td align="left" colspan="2" rowspan="1">Lynch et al. <xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref></td>
                <td align="left" colspan="2" rowspan="1">O'Brien et al. <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref></td>
                <td align="left" colspan="2" rowspan="1">Pirker et al. <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref></td>
                <td align="left" colspan="2" rowspan="1">Ridolfi et al. <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref></td>
                <td align="left" colspan="2" rowspan="1">Rosell et al. <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref></td>
                <td align="left" colspan="2" rowspan="1">Zhong et al. <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
                <td align="left" colspan="1" rowspan="1">Exp</td>
                <td align="left" colspan="1" rowspan="1">Con</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 51</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 50</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 44</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 44</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 338</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 338</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 210</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 209</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 557</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 568</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 127</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 114</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 43</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 43</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 14</td>
                <td align="left" colspan="1" rowspan="1"><italic>n</italic> = 14</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Anemia</td>
                <td align="left" colspan="1" rowspan="1">8</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">17</td>
                <td align="left" colspan="1" rowspan="1">15</td>
                <td align="left" colspan="1" rowspan="1">71</td>
                <td align="left" colspan="1" rowspan="1">54</td>
                <td align="left" colspan="1" rowspan="1">76</td>
                <td align="left" colspan="1" rowspan="1">94</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">6</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Leucopenia</td>
                <td align="left" colspan="1" rowspan="1">17</td>
                <td align="left" colspan="1" rowspan="1">18</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">138</td>
                <td align="left" colspan="1" rowspan="1">97</td>
                <td align="left" colspan="1" rowspan="1">55</td>
                <td align="left" colspan="1" rowspan="1">49</td>
                <td align="left" colspan="1" rowspan="1">139</td>
                <td align="left" colspan="1" rowspan="1">109</td>
                <td align="left" colspan="1" rowspan="1">22</td>
                <td align="left" colspan="1" rowspan="1">19</td>
                <td align="left" colspan="1" rowspan="1">26</td>
                <td align="left" colspan="1" rowspan="1">20</td>
                <td align="left" colspan="1" rowspan="1">10</td>
                <td align="left" colspan="1" rowspan="1">13</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neutropenia</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">5</td>
                <td align="left" colspan="1" rowspan="1">7</td>
                <td align="left" colspan="1" rowspan="1">198</td>
                <td align="left" colspan="1" rowspan="1">177</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">289</td>
                <td align="left" colspan="1" rowspan="1">289</td>
                <td align="left" colspan="1" rowspan="1">58</td>
                <td align="left" colspan="1" rowspan="1">45</td>
                <td align="left" colspan="1" rowspan="1">36</td>
                <td align="left" colspan="1" rowspan="1">23</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
                <td align="left" colspan="1" rowspan="1">18</td>
                <td align="left" colspan="1" rowspan="1">17</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">33</td>
                <td align="left" colspan="1" rowspan="1">29</td>
                <td align="left" colspan="1" rowspan="1">48</td>
                <td align="left" colspan="1" rowspan="1">34</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">64</td>
                <td align="left" colspan="1" rowspan="1">36</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nausea</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">5</td>
                <td align="left" colspan="1" rowspan="1">7</td>
                <td align="left" colspan="1" rowspan="1">18</td>
                <td align="left" colspan="1" rowspan="1">15</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">22</td>
                <td align="left" colspan="1" rowspan="1">23</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypertension</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Diarrhea</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">17</td>
                <td align="left" colspan="1" rowspan="1">8</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">25</td>
                <td align="left" colspan="1" rowspan="1">13</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dyspnea</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">47</td>
                <td align="left" colspan="1" rowspan="1">51</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neurosensory toxicity</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">5</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypomagnesemia</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">26</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt109">
              <label>*</label>
              <p>No treatment-related adverse events (grade ≥3) were observed in trials by Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref> and Wu et al. <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref>; serious adverse events occurred significantly less frequently in immunotherapy groups than in control groups, but no detailed data were presented in studies by Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref> and Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>.</p>
            </fn>
            <fn id="nt110">
              <label/>
              <p>Note: Exp: experimental group; Con: control group; ND: adverse events (grades ≥3) were not described.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <table-wrap id="pone-0032695-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t005</object-id><label>Table 5</label><caption>
            <title>Adverse events (grade ≥3) in overall immunotherapy and subgroups of advanced NSCLC patients.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t005-5" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t005" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <italic>Groups</italic>
                </td>
                <td align="left" colspan="3" rowspan="1"><italic>Overall immunotherapy </italic><xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[<italic>23</italic>]</xref>–<xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
                <td align="left" colspan="3" rowspan="1"><italic>Cytokines subgroup </italic><xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[<italic>23</italic>]</xref>, <xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>, <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref></td>
                <td align="left" colspan="3" rowspan="1">
                  <italic>Vaccines subgroup </italic>
                  <xref ref-type="bibr" rid="pone.0032695-OBrien1">[<italic>26</italic>]</xref>
                </td>
                <td align="left" colspan="3" rowspan="1"><italic>mAbs subgroup </italic><xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[<italic>24</italic>]</xref>, <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31<italic/>]</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Adverse events</td>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
                <td align="left" colspan="1" rowspan="1">OR</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Anemia</td>
                <td align="left" colspan="1" rowspan="1">1.00</td>
                <td align="left" colspan="1" rowspan="1">0.80–1.25</td>
                <td align="left" colspan="1" rowspan="1">0.9787</td>
                <td align="left" colspan="1" rowspan="1">0.88</td>
                <td align="left" colspan="1" rowspan="1">0.67–1.16</td>
                <td align="left" colspan="1" rowspan="1">0.3659</td>
                <td align="left" colspan="1" rowspan="1">1.47</td>
                <td align="left" colspan="1" rowspan="1">0.96–2.23</td>
                <td align="left" colspan="1" rowspan="1">0.0752</td>
                <td align="left" colspan="1" rowspan="1">0.61</td>
                <td align="left" colspan="1" rowspan="1">0.17–2.20</td>
                <td align="left" colspan="1" rowspan="1">0.4522</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Diarrhea</td>
                <td align="left" colspan="1" rowspan="1">2.03</td>
                <td align="left" colspan="1" rowspan="1">1.21–3.40</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0074</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">2.07</td>
                <td align="left" colspan="1" rowspan="1">1.21–3.51</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0075</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">1.87</td>
                <td align="left" colspan="1" rowspan="1">0.17–20.80</td>
                <td align="left" colspan="1" rowspan="1">0.6110</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dyspnea</td>
                <td align="left" colspan="1" rowspan="1">0.90</td>
                <td align="left" colspan="1" rowspan="1">0.60–1.34</td>
                <td align="left" colspan="1" rowspan="1">0.5987</td>
                <td align="left" colspan="1" rowspan="1">0.93</td>
                <td align="left" colspan="1" rowspan="1">0.62–1.39</td>
                <td align="left" colspan="1" rowspan="1">0.72</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">0.31</td>
                <td align="left" colspan="1" rowspan="1">0.01–7.62</td>
                <td align="left" colspan="1" rowspan="1">0.4720</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypertension</td>
                <td align="left" colspan="1" rowspan="1">0.75</td>
                <td align="left" colspan="1" rowspan="1">0.17–3.34</td>
                <td align="left" colspan="1" rowspan="1">0.7032</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">0.69</td>
                <td align="left" colspan="1" rowspan="1">0.15–3.14</td>
                <td align="left" colspan="1" rowspan="1">0.6335</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypomagnesemia</td>
                <td align="left" colspan="1" rowspan="1">9.13</td>
                <td align="left" colspan="1" rowspan="1">2.76–30.17</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0003</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">13.46</td>
                <td align="left" colspan="1" rowspan="1">3.19–56.86</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0004</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">0.93</td>
                <td align="left" colspan="1" rowspan="1">0.06–14.97</td>
                <td align="left" colspan="1" rowspan="1">0.9588</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Leucopenia</td>
                <td align="left" colspan="1" rowspan="1">1.35</td>
                <td align="left" colspan="1" rowspan="1">1.14–1.60</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0005</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">1.48</td>
                <td align="left" colspan="1" rowspan="1">1.22–1.80</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0001</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">1.16</td>
                <td align="left" colspan="1" rowspan="1">0.74–1.81</td>
                <td align="left" colspan="1" rowspan="1">0.5155</td>
                <td align="left" colspan="1" rowspan="1">0.92</td>
                <td align="left" colspan="1" rowspan="1">0.53–1.57</td>
                <td align="left" colspan="1" rowspan="1">0.7477</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nausea</td>
                <td align="left" colspan="1" rowspan="1">1.02</td>
                <td align="left" colspan="1" rowspan="1">0.68–1.53</td>
                <td align="left" colspan="1" rowspan="1">0.9292</td>
                <td align="left" colspan="1" rowspan="1">1.24</td>
                <td align="left" colspan="1" rowspan="1">0.66–2.33</td>
                <td align="left" colspan="1" rowspan="1">0.5030</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">0.81</td>
                <td align="left" colspan="1" rowspan="1">0.46–1.43</td>
                <td align="left" colspan="1" rowspan="1">0.4635</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neurosensory toxicity</td>
                <td align="left" colspan="1" rowspan="1">1.66</td>
                <td align="left" colspan="1" rowspan="1">0.40–6.98</td>
                <td align="left" colspan="1" rowspan="1">0.4861</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">1.56</td>
                <td align="left" colspan="1" rowspan="1">0.37–6.65</td>
                <td align="left" colspan="1" rowspan="1">0.5441</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neutropenia</td>
                <td align="left" colspan="1" rowspan="1">1.14</td>
                <td align="left" colspan="1" rowspan="1">0.98–1.32</td>
                <td align="left" colspan="1" rowspan="1">0.0962</td>
                <td align="left" colspan="1" rowspan="1">1.17</td>
                <td align="left" colspan="1" rowspan="1">0.98–1.40</td>
                <td align="left" colspan="1" rowspan="1">0.0765</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">1.19</td>
                <td align="left" colspan="1" rowspan="1">0.76–1.86</td>
                <td align="left" colspan="1" rowspan="1">0.4403</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
                <td align="left" colspan="1" rowspan="1">1.46</td>
                <td align="left" colspan="1" rowspan="1">1.14–1.88</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0029</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">1.15</td>
                <td align="left" colspan="1" rowspan="1">0.77–1.72</td>
                <td align="left" colspan="1" rowspan="1">0.5049</td>
                <td align="left" colspan="1" rowspan="1">1.53</td>
                <td align="left" colspan="1" rowspan="1">0.94–2.49</td>
                <td align="left" colspan="1" rowspan="1">0.0904</td>
                <td align="left" colspan="1" rowspan="1">2.00</td>
                <td align="left" colspan="1" rowspan="1">1.24–3.22</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0044</bold>
                </td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt111">
              <label/>
              <p>Note: mAbs, monoclonal antibodies; OR, odds ratio. CI, confidence interval. No treatment-related adverse events (grade ≥3) were observed in trials by Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref> and Wu et al. <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref>; serious adverse events occurred but significantly less frequently in immunotherapy groups than in control groups and no detailed data were presented in studies by Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref> and Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <table-wrap id="pone-0032695-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t006</object-id><label>Table 6</label><caption>
            <title>Adverse events (grade ≥3) in overall immunotherapy and subgroups of advanced NSCLC patients.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t006-6" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t006" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1"><italic>Overall immunotherapy </italic><xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[<italic>23]</italic></xref>–<xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31<italic/>]</xref></td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>Experimental (N = 1384)</italic>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>Control (N = 1380)</italic>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>Odds ratio</italic>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>95% CI</italic>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <italic>P-value</italic>
                </td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Anemia</td>
                <td align="left" colspan="1" rowspan="1">182</td>
                <td align="left" colspan="1" rowspan="1">181</td>
                <td align="left" colspan="1" rowspan="1">1.0030</td>
                <td align="left" colspan="1" rowspan="1">0.80–1.25</td>
                <td align="left" colspan="1" rowspan="1">0.9787</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Diarrhea</td>
                <td align="left" colspan="1" rowspan="1">44</td>
                <td align="left" colspan="1" rowspan="1">22</td>
                <td align="left" colspan="1" rowspan="1">2.0269</td>
                <td align="left" colspan="1" rowspan="1">1.21–3.40</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0074</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dyspnea</td>
                <td align="left" colspan="1" rowspan="1">47</td>
                <td align="left" colspan="1" rowspan="1">52</td>
                <td align="left" colspan="1" rowspan="1">0.8978</td>
                <td align="left" colspan="1" rowspan="1">0.60–1.34</td>
                <td align="left" colspan="1" rowspan="1">0.5987</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypertension</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">0.7473</td>
                <td align="left" colspan="1" rowspan="1">0.17–3.34</td>
                <td align="left" colspan="1" rowspan="1">0.7032</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypomagnesemia</td>
                <td align="left" colspan="1" rowspan="1">27</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">9.1326</td>
                <td align="left" colspan="1" rowspan="1">2.76–30.17</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0003</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Leucopenia</td>
                <td align="left" colspan="1" rowspan="1">407</td>
                <td align="left" colspan="1" rowspan="1">325</td>
                <td align="left" colspan="1" rowspan="1">1.3523</td>
                <td align="left" colspan="1" rowspan="1">1.14–1.60</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0005</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nausea</td>
                <td align="left" colspan="1" rowspan="1">49</td>
                <td align="left" colspan="1" rowspan="1">48</td>
                <td align="left" colspan="1" rowspan="1">1.0185</td>
                <td align="left" colspan="1" rowspan="1">0.68–1.53</td>
                <td align="left" colspan="1" rowspan="1">0.9292</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neurosensory toxicity</td>
                <td align="left" colspan="1" rowspan="1">5</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">1.6642</td>
                <td align="left" colspan="1" rowspan="1">0.40–6.98</td>
                <td align="left" colspan="1" rowspan="1">0.4861</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neutropenia</td>
                <td align="left" colspan="1" rowspan="1">615</td>
                <td align="left" colspan="1" rowspan="1">570</td>
                <td align="left" colspan="1" rowspan="1">1.1365</td>
                <td align="left" colspan="1" rowspan="1">0.98–1.32</td>
                <td align="left" colspan="1" rowspan="1">0.0962</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
                <td align="left" colspan="1" rowspan="1">165</td>
                <td align="left" colspan="1" rowspan="1">117</td>
                <td align="left" colspan="1" rowspan="1">1.4612</td>
                <td align="left" colspan="1" rowspan="1">1.14–1.88</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0029</bold>
                </td>
              </tr>
            </tbody>
          </table><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Adverse event items in cytokines subgroup <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref>, <xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>, <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref></td>
                <td align="left" colspan="1" rowspan="1">Experimental (<italic>N</italic> = 989)</td>
                <td align="left" colspan="1" rowspan="1">Control (<italic>N</italic> = 999)</td>
                <td align="left" colspan="1" rowspan="1">Odds ratio</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Anemia</td>
                <td align="left" colspan="1" rowspan="1">107</td>
                <td align="left" colspan="1" rowspan="1">121</td>
                <td align="left" colspan="1" rowspan="1">0.88</td>
                <td align="left" colspan="1" rowspan="1">0.67–1.16</td>
                <td align="left" colspan="1" rowspan="1">0.3659</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Diarrhea</td>
                <td align="left" colspan="1" rowspan="1">42</td>
                <td align="left" colspan="1" rowspan="1">21</td>
                <td align="left" colspan="1" rowspan="1">2.07</td>
                <td align="left" colspan="1" rowspan="1">1.21–3.51</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0075</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dyspnea</td>
                <td align="left" colspan="1" rowspan="1">47</td>
                <td align="left" colspan="1" rowspan="1">51</td>
                <td align="left" colspan="1" rowspan="1">0.93</td>
                <td align="left" colspan="1" rowspan="1">0.62–1.39</td>
                <td align="left" colspan="1" rowspan="1">0.72</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypertension</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypomagnesemia</td>
                <td align="left" colspan="1" rowspan="1">26</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">13.46</td>
                <td align="left" colspan="1" rowspan="1">3.19–56.86</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0004</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Leucopenia</td>
                <td align="left" colspan="1" rowspan="1">320</td>
                <td align="left" colspan="1" rowspan="1">244</td>
                <td align="left" colspan="1" rowspan="1">1.48</td>
                <td align="left" colspan="1" rowspan="1">1.22–1.80</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0001</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nausea</td>
                <td align="left" colspan="1" rowspan="1">22</td>
                <td align="left" colspan="1" rowspan="1">18</td>
                <td align="left" colspan="1" rowspan="1">1.24</td>
                <td align="left" colspan="1" rowspan="1">0.66–2.33</td>
                <td align="left" colspan="1" rowspan="1">0.5030</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neurosensory toxicity</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neutropenia</td>
                <td align="left" colspan="1" rowspan="1">552</td>
                <td align="left" colspan="1" rowspan="1">518</td>
                <td align="left" colspan="1" rowspan="1">1.17</td>
                <td align="left" colspan="1" rowspan="1">0.98–1.40</td>
                <td align="left" colspan="1" rowspan="1">0.0765</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
                <td align="left" colspan="1" rowspan="1">53</td>
                <td align="left" colspan="1" rowspan="1">47</td>
                <td align="left" colspan="1" rowspan="1">1.15</td>
                <td align="left" colspan="1" rowspan="1">0.77–1.72</td>
                <td align="left" colspan="1" rowspan="1">0.5049</td>
              </tr>
            </tbody>
          </table><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Adverse event items in vaccines subgroup <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref></td>
                <td align="left" colspan="1" rowspan="1">Experimental (<italic>N</italic> = 210)</td>
                <td align="left" colspan="1" rowspan="1">Control (<italic>N</italic> = 209)</td>
                <td align="left" colspan="1" rowspan="1">Odds ratio</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1">P-value</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Anemia</td>
                <td align="left" colspan="1" rowspan="1">71</td>
                <td align="left" colspan="1" rowspan="1">54</td>
                <td align="left" colspan="1" rowspan="1">1.47</td>
                <td align="left" colspan="1" rowspan="1">0.96–2.23</td>
                <td align="left" colspan="1" rowspan="1">0.0752</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Diarrhea</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dyspnea</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypertension</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypomagnesemia</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Leucopenia</td>
                <td align="left" colspan="1" rowspan="1">55</td>
                <td align="left" colspan="1" rowspan="1">49</td>
                <td align="left" colspan="1" rowspan="1">1.16</td>
                <td align="left" colspan="1" rowspan="1">0.74–1.81</td>
                <td align="left" colspan="1" rowspan="1">0.5155</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nausea</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neurosensory toxicity</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neutropenia</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
                <td align="left" colspan="1" rowspan="1">/</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
                <td align="left" colspan="1" rowspan="1">48</td>
                <td align="left" colspan="1" rowspan="1">34</td>
                <td align="left" colspan="1" rowspan="1">1.53</td>
                <td align="left" colspan="1" rowspan="1">0.94–2.49</td>
                <td align="left" colspan="1" rowspan="1">0.0904</td>
              </tr>
            </tbody>
          </table><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Adverse event items in mAbs subgroup <xref ref-type="bibr" rid="pone.0032695-LasalviaPrisco1">[24]</xref>, <xref ref-type="bibr" rid="pone.0032695-Ridolfi1">[28]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref></td>
                <td align="left" colspan="1" rowspan="1">Experimental (<italic>N</italic> = 185)</td>
                <td align="left" colspan="1" rowspan="1">Control (<italic>N</italic> = 172)</td>
                <td align="left" colspan="1" rowspan="1">Odds ratio</td>
                <td align="left" colspan="1" rowspan="1">95% CI</td>
                <td align="left" colspan="1" rowspan="1"><italic>P</italic>-value</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Anemia</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">6</td>
                <td align="left" colspan="1" rowspan="1">0.61</td>
                <td align="left" colspan="1" rowspan="1">0.17–2.20</td>
                <td align="left" colspan="1" rowspan="1">0.4522</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Diarrhea</td>
                <td align="left" colspan="1" rowspan="1">2</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">1.87</td>
                <td align="left" colspan="1" rowspan="1">0.17–20.80</td>
                <td align="left" colspan="1" rowspan="1">0.6110</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Dyspnea</td>
                <td align="left" colspan="1" rowspan="1">0</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">0.31</td>
                <td align="left" colspan="1" rowspan="1">0.01–7.62</td>
                <td align="left" colspan="1" rowspan="1">0.4720</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypertension</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">4</td>
                <td align="left" colspan="1" rowspan="1">0.69</td>
                <td align="left" colspan="1" rowspan="1">0.15–3.14</td>
                <td align="left" colspan="1" rowspan="1">0.6335</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Hypomagnesemia</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">1</td>
                <td align="left" colspan="1" rowspan="1">0.93</td>
                <td align="left" colspan="1" rowspan="1">0.06–14.97</td>
                <td align="left" colspan="1" rowspan="1">0.9588</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Leucopenia</td>
                <td align="left" colspan="1" rowspan="1">32</td>
                <td align="left" colspan="1" rowspan="1">32</td>
                <td align="left" colspan="1" rowspan="1">0.92</td>
                <td align="left" colspan="1" rowspan="1">0.53–1.57</td>
                <td align="left" colspan="1" rowspan="1">0.7477</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nausea</td>
                <td align="left" colspan="1" rowspan="1">27</td>
                <td align="left" colspan="1" rowspan="1">30</td>
                <td align="left" colspan="1" rowspan="1">0.81</td>
                <td align="left" colspan="1" rowspan="1">0.46–1.43</td>
                <td align="left" colspan="1" rowspan="1">0.4635</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neurosensory toxicity</td>
                <td align="left" colspan="1" rowspan="1">5</td>
                <td align="left" colspan="1" rowspan="1">3</td>
                <td align="left" colspan="1" rowspan="1">1.56</td>
                <td align="left" colspan="1" rowspan="1">0.37–6.65</td>
                <td align="left" colspan="1" rowspan="1">0.5441</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Neutropenia</td>
                <td align="left" colspan="1" rowspan="1">63</td>
                <td align="left" colspan="1" rowspan="1">52</td>
                <td align="left" colspan="1" rowspan="1">1.19</td>
                <td align="left" colspan="1" rowspan="1">0.76–1.86</td>
                <td align="left" colspan="1" rowspan="1">0.4403</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Thrombocytopenia</td>
                <td align="left" colspan="1" rowspan="1">64</td>
                <td align="left" colspan="1" rowspan="1">36</td>
                <td align="left" colspan="1" rowspan="1">2.00</td>
                <td align="left" colspan="1" rowspan="1">1.24–3.22</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.0044</bold>
                </td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt112">
              <label/>
              <p>Note: No treatment-related adverse events (grade ≥3) were observed in trials by Neninger Vinageras et al. <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref> and Wu et al. <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref>; serious adverse events occurred but significantly less frequently in immunotherapy groups versus control groups and no details were provided by Lissoni et al. <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref> and Butts et al. <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>. mAbs, monoclonal antibodies; CI, confidence interval. ND: the corresponding adverse events (grades ≥3) were not described.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <table-wrap id="pone-0032695-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0032695.t007</object-id><label>Table 7</label><caption>
            <title>Efficacy analysis on overall immunotherapy and subgroups.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pone-0032695-t007-7" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0032695.t007" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Efficacy parameters</td>
                <td align="left" colspan="1" rowspan="1">Overall immunotherapy</td>
                <td align="left" colspan="1" rowspan="1">Vaccine</td>
                <td align="left" colspan="1" rowspan="1">Cytokine</td>
                <td align="left" colspan="1" rowspan="1">Monoclonal antibody</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Overall survival</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">S</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Progression-free survival<xref ref-type="table-fn" rid="nt117">a</xref></td>
                <td align="left" colspan="1" rowspan="1">SS</td>
                <td align="left" colspan="1" rowspan="1">ND</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Total effective rate</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Partial response</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">SS</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Complete response</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Adverse events<xref ref-type="table-fn" rid="nt118">b</xref></td>
                <td align="left" colspan="1" rowspan="1">++++</td>
                <td align="left" colspan="1" rowspan="1">NS/ND</td>
                <td align="left" colspan="1" rowspan="1">+++</td>
                <td align="left" colspan="1" rowspan="1">+</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt113">
              <label/>
              <p>S, barely significant with <italic>P</italic> = 0.05.</p>
            </fn>
            <fn id="nt114">
              <label/>
              <p>SS, substantially significant difference at 0.01 level between immunotherapy arm and the corresponding control arm.</p>
            </fn>
            <fn id="nt115">
              <label/>
              <p>NS, no significant difference compared to the corresponding control arm.</p>
            </fn>
            <fn id="nt116">
              <label/>
              <p>ND, no detailed data were described for.</p>
            </fn>
            <fn id="nt117">
              <label>a</label>
              <p>progress-free survival in vaccine-adopted trials and.</p>
            </fn>
            <fn id="nt118">
              <label>b</label>
              <p>adverse events (grades ≥3) in four vaccine or cytokine trials <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-Butts1">[22]</xref>, <xref ref-type="bibr" rid="pone.0032695-Wu2">[30]</xref>.</p>
            </fn>
            <fn id="nt119">
              <label/>
              <p>Each plus (+) represents one kind of adverse event (grades ≥3) for which the immunotherapy arm was significantly greater.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>The 12 trials included in this meta-analysis adopted three kinds of immunotherapy (vaccines, cytokines, mAbs) for advanced NSCLC patients. Hence the number of published randomized controlled trials for each kind of immunotherapy would affect the results of this study. The quality of the reported data influenced the power of our meta-analysis, and greater statistical reliability would be achieved if additional and more comprehensive trials including all of the efficacy parameters were enrolled. Nevertheless, sensitivity analyses on the various efficacy parameters with alternative exclusions of one of the trials supported the conclusions drawn from the overall unstratified analyses. Other factors, such as race differences of patients, curative agents administrated simultaneously with immunotherapy, different immunotherapy strategies, different lengths of follow-up, and different proportions lost to follow-up may confer limitations on this meta-analysis. In overall studies, no significant publication bias existed <xref ref-type="bibr" rid="pone.0032695-Begg1">[32]</xref>. To avoid bias in the identification and selection of studies, as many randomized controlled trials as possible were included to improve the statistical reliability. Our literature search strategy guaranteed that there was less possibility of important published trials being overlooked. According to our meta-analysis, all patients with advanced NSCLC met quality-control specifications and protocol eligibility <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>–<xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref>. Subgroup analyses were conducted according to recently proposed criteria <xref ref-type="bibr" rid="pone.0032695-Huncharek1">[33]</xref>, <xref ref-type="bibr" rid="pone.0032695-Sun1">[34]</xref>, and their validity was enhanced by the fine discrimination of the subgroups of 12 immunotherapy trials. Finally, Kaplan-Meier estimation of hazard ratios demonstrated that no statistical inconsistency existed between the results from each of the original studies and those of the overall or subgroup analyses of immunotherapy efficacy, suggesting that the results of this meta-analysis are valid.</p>
      <p>Roughly two-thirds of lung cancer patients have locally advanced or disseminated diseases, and surgery is not adopted at the time of diagnosis <xref ref-type="bibr" rid="pone.0032695-Yasumoto1">[3]</xref>. Therefore, efficient alternative therapy is needed. The results of the overall meta-analysis showed that immunotherapy significantly improved the PFS, total effective rate, and PR rate (<italic>P</italic> = 0.0004, 0.003, 0.002, respectively) in despite of less influence on the CR rate (<italic>P</italic> = 0.97), suggesting that immunotherapy may provide advantages for patients with advanced NSCLC. However, immunotherapeutic approaches in the treatment of NSCLC were always applied based on standard treatment modalities or in combination with multiple immunotherapeutic agents rather than as single-agent therapy <xref ref-type="bibr" rid="pone.0032695-Lissoni1">[16]</xref>, <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>–<xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref>. Subgroup analyses showed that only mAb-treated group significantly benefited from immunotherapy with regard to PFS, total effective rate, and PR rate (<italic>P</italic> = 0.0002, 0.0006, 0.001, respectively), with a trend of improvement in OS (<italic>P</italic> = 0.05). The vaccine-treated group achieved significant improvement only in OS (<italic>P</italic> = 0.009), and cytokines-treated group did not significantly improve OS, total effective rate, PR rate (<italic>P</italic> = 0.08, 0.81, 0.71, respectively). Furthermore, all three subgroups did not improve the CR rates (<xref ref-type="table" rid="pone-0032695-t006">Table 6</xref>).</p>
      <p>Vaccine and cytokine immunotherapies are novel modalities for the treatment of advanced NSCLC <xref ref-type="bibr" rid="pone.0032695-NeningerVinageras1">[21]</xref>, <xref ref-type="bibr" rid="pone.0032695-OBrien1">[26]</xref>, <xref ref-type="bibr" rid="pone.0032695-Zhong1">[31]</xref>, <xref ref-type="bibr" rid="pone.0032695-Perroud1">[35]</xref>–<xref ref-type="bibr" rid="pone.0032695-Garcia1">[38]</xref>, and specific immune responses have been documented in many advanced NSCLC studies <xref ref-type="bibr" rid="pone.0032695-Raez1">[9]</xref>, <xref ref-type="bibr" rid="pone.0032695-Nemunaitis2">[37]</xref>. Our meta-analysis showed, however, that no significant clinical efficacy was achieved by the two kinds of immunotherapy when they were applied to advanced NSCLC patients. In addition, cytokine immunotherapy significantly induced several kinds of treatment-related AEs. Taken together, mAb immunotherapy was considered to be the most potential therapy for advanced NSCLC patients compared with other immunotherapy strategies.</p>
      <p>The importance of AEs and toxicity must be emphasized. Although mAb immunotherapy could improve efficacy, more AEs or toxicity occurred in mAb immunotherapy groups than in control groups, which may discount the efficacy of immunotherapy and lower the CR rate. To further improve the efficacy of immunotherapy, researchers should develop immunotherapeutic regimens to reduce or eliminate toxicity and AEs, which can further improve the quality of life of advanced NSCLC patients. In fact, aside from individual differences, drug dose, and administration protocols, the molecular structure of the drug protein <xref ref-type="bibr" rid="pone.0032695-Strand1">[39]</xref> is the most important factor related to efficacy and safety of immunotherapy.</p>
      <p>In the past two decades, 32 mAb drugs have been approved by U.S. Food and Drug Administration, but two of the three drugs that could be involved in preclinical trials have been withdrawn from the market due to their serious adverse events in human patients <xref ref-type="bibr" rid="pone.0032695-Bettauer1">[40]</xref>. The mAbs can be quickly developed and demonstrated to be efficacious for advanced NSCLC patients. However, mAbs immunotherapy-associated AEs and anaphylaxis could timely occur <xref ref-type="bibr" rid="pone.0032695-Gatzemeier1">[23]</xref>, <xref ref-type="bibr" rid="pone.0032695-Lynch1">[25]</xref>, <xref ref-type="bibr" rid="pone.0032695-Pirker1">[27]</xref>, <xref ref-type="bibr" rid="pone.0032695-Rosell1">[29]</xref> or be delayed with the treatment process <xref ref-type="bibr" rid="pone.0032695-Limb1">[41]</xref>. To minimize AEs or anaphylaxis, further researches on two aspects are merited. First, because even mAb containing less than 10% mouse-derived fragments (i.e., ≥90% humanized) can result in AEs <xref ref-type="bibr" rid="pone.0032695-Cox2">[42]</xref>, fully humanized mAbs should be developed to eliminate mouse epitopes. Second, the allergenicity of mAbs should be further attenuated and/or eliminated. The resolution of these two issues would allow the development of more efficacious and safer agents for immunotherapy treatment of advanced NSCLC.</p>
      <p>In conclusion, anticancer therapy should be performed based on an individual assessment of the risk of recurrence and death caused by the therapy, i.e. the balance between toxicity and efficacy, and even changes in quality of life <xref ref-type="bibr" rid="pone.0032695-Hamada1">[43]</xref>. The efficacy and safety of new therapies must be assessed appropriately for physicians to decide how to select the optimal treatment strategy. We found that immunotherapy using mAbs, rather than cytokines and vaccines, could significantly improved PFS, total effective rate, and PR rate, suggesting that mAb immunotherapy may become a standard complementary therapeutic approach for advanced NSCLC patients in the future. In despite of this, more efficacious and safer (i.e., causing fewer AEs and less allergenicity) immunotherapeutic agents should also be developed.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to Drs Xue-Ting Liu and Ji-Fu Wei for their critical reading of the manuscript.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0032695-Jemal1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Center</surname><given-names>MM</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Ward</surname><given-names>E</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Global cancer statistics.</article-title>             <source>CA Cancer J Clin</source>             <volume>61</volume>             <fpage>69</fpage>             <lpage>90</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Gridelli1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gridelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>A</given-names></name><name name-style="western"><surname>Maione</surname><given-names>P</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>ML</given-names></name><name name-style="western"><surname>Castaldo</surname><given-names>V</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Vaccines for the treatment of non-small-cell lung cancer: a renewed anticancer strategy.</article-title>             <source>Oncologist</source>             <volume>14</volume>             <fpage>909</fpage>             <lpage>920</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Yasumoto1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yasumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Hanagiri</surname><given-names>T</given-names></name><name name-style="western"><surname>Takenoyama</surname><given-names>M</given-names></name></person-group>             <year>2009</year>             <article-title>Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.</article-title>             <source>Gen Thorac Cardiovasc Surg</source>             <volume>57</volume>             <fpage>449</fpage>             <lpage>457</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Kakimi1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kakimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>J</given-names></name><name name-style="western"><surname>Wada</surname><given-names>H</given-names></name></person-group>             <year>2009</year>             <article-title>Active specific immunotherapy and cell-transfer therapy for the treatment of non-small-cell lung cancer.</article-title>             <source>Lung Cancer</source>             <volume>65</volume>             <fpage>1</fpage>             <lpage>8</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Palmer1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>M</given-names></name><name name-style="western"><surname>Parker</surname><given-names>J</given-names></name><name name-style="western"><surname>Modi</surname><given-names>S</given-names></name><name name-style="western"><surname>Butts</surname><given-names>C</given-names></name><name name-style="western"><surname>Smylie</surname><given-names>M</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.</article-title>             <source>Clin Lung Cancer</source>             <volume>3</volume>             <fpage>49</fpage>             <lpage>57</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Gadgeel1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gadgeel</surname><given-names>SM</given-names></name></person-group>             <year>2011</year>             <article-title>The optimal chemotherapy for stage III non-small cell lung cancer patients.</article-title>             <source>Curr Oncol Rep</source>             <volume>13</volume>             <fpage>272</fpage>             <lpage>279</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Chrischilles1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chrischilles</surname><given-names>EA</given-names></name><name name-style="western"><surname>Pendergast</surname><given-names>JF</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>KL</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>RB</given-names></name><name name-style="western"><surname>Moga</surname><given-names>DC</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.</article-title>             <source>J Clin Oncol</source>             <volume>28</volume>             <fpage>620</fpage>             <lpage>627</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Holt1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Holt</surname><given-names>GE</given-names></name><name name-style="western"><surname>Podack</surname><given-names>ER</given-names></name><name name-style="western"><surname>Raez</surname><given-names>LE</given-names></name></person-group>             <year>2011</year>             <article-title>Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.</article-title>             <source>Therapy</source>             <volume>8</volume>             <fpage>43</fpage>             <lpage>54</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Raez1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Raez</surname><given-names>LE</given-names></name><name name-style="western"><surname>Cassileth</surname><given-names>PA</given-names></name><name name-style="western"><surname>Schlesselman</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>K</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>S</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.</article-title>             <source>J Clin Oncol</source>             <volume>22</volume>             <fpage>2800</fpage>             <lpage>2807</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Morgensztern1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Morgensztern</surname><given-names>D</given-names></name><name name-style="western"><surname>Goodgame</surname><given-names>B</given-names></name><name name-style="western"><surname>Govindan</surname><given-names>R</given-names></name></person-group>             <year>2010</year>             <article-title>Vaccines and immunotherapy for non-small-cell lung cancer.</article-title>             <source>J Thorac Oncol</source>             <volume>5</volume>             <fpage>S463</fpage>             <lpage>465</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Moher1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group>             <year>2009</year>             <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.</article-title>             <source>PLoS Med</source>             <volume>6</volume>             <fpage>e1000097</fpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Jadad1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jadad</surname><given-names>AR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>RA</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>C</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>DJ</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</article-title>             <source>Control Clin Trials</source>             <volume>17</volume>             <fpage>1</fpage>             <lpage>12</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Rao1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>B</given-names></name><name name-style="western"><surname>Han</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.</article-title>             <source>J Transl Med</source>             <volume>9</volume>             <fpage>17</fpage>             <lpage>27</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Clark1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>HD</given-names></name><name name-style="western"><surname>Wells</surname><given-names>GA</given-names></name><name name-style="western"><surname>Huet</surname><given-names>C</given-names></name><name name-style="western"><surname>McAlister</surname><given-names>FA</given-names></name><name name-style="western"><surname>Salmi</surname><given-names>LR</given-names></name><etal/></person-group>             <year>1999</year>             <article-title>Assessing the quality of randomized trials: reliability of the Jadad scale.</article-title>             <source>Control Clin Trials</source>             <volume>20</volume>             <fpage>448</fpage>             <lpage>452</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Wu1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Keresztes</surname><given-names>RS</given-names></name></person-group>             <year>2011</year>             <article-title>Antiangiogenic agents for the treatment of non-small-cell lung cancer: characterizing the molecular basis for serious adverse events.</article-title>             <source>Cancer Invest</source>             <volume>29</volume>             <fpage>460</fpage>             <lpage>471</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Lissoni1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lissoni</surname><given-names>P</given-names></name><name name-style="western"><surname>Meregalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>V</given-names></name><name name-style="western"><surname>Paolorossi</surname><given-names>F</given-names></name><name name-style="western"><surname>Barni</surname><given-names>S</given-names></name><etal/></person-group>             <year>1994</year>             <article-title>A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small-cell lung cancer.</article-title>             <source>Tumori</source>             <volume>80</volume>             <fpage>464</fpage>             <lpage>467</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Bradburn1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bradburn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Russell Localio</surname><given-names>A</given-names></name></person-group>             <year>2007</year>             <article-title>Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.</article-title>             <source>Stat Med</source>             <volume>26</volume>             <fpage>53</fpage>             <lpage>77</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Cox1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>DR</given-names></name></person-group>             <year>1972</year>             <article-title>Regression models and life-tables.</article-title>             <source>J Royal Statistical Soc B (Methodological)</source>             <volume>B34</volume>             <fpage>187</fpage>             <lpage>220</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Thatcher1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Thatcher</surname><given-names>N</given-names></name><name name-style="western"><surname>Heighway</surname><given-names>J</given-names></name></person-group>             <year>2010</year>             <article-title>Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small-cell lung cancer.</article-title>             <source>Oncologist</source>             <volume>15</volume>             <fpage>1034</fpage>             <lpage>1042</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Higgins1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>J</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>S</given-names></name></person-group>             <year>2002</year>             <article-title>Quantifying heterogeneity in a meta-analysis.</article-title>             <source>Stat Med</source>             <volume>21</volume>             <fpage>1539</fpage>             <lpage>1558</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-NeningerVinageras1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Neninger Vinageras</surname><given-names>E</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>A</given-names></name><name name-style="western"><surname>Osorio Rodriguez</surname><given-names>M</given-names></name><name name-style="western"><surname>Catala Ferrer</surname><given-names>M</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>I</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.</article-title>             <source>J Clin Oncol</source>             <volume>26</volume>             <fpage>1452</fpage>             <lpage>1458</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Butts1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Butts</surname><given-names>C</given-names></name><name name-style="western"><surname>Murray</surname><given-names>N</given-names></name><name name-style="western"><surname>Maksymiuk</surname><given-names>A</given-names></name><name name-style="western"><surname>Goss</surname><given-names>G</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>E</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.</article-title>             <source>J Clin Oncol</source>             <volume>23</volume>             <fpage>6674</fpage>             <lpage>6681</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Gatzemeier1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gatzemeier</surname><given-names>U</given-names></name><name name-style="western"><surname>Groth</surname><given-names>G</given-names></name><name name-style="western"><surname>Butts</surname><given-names>C</given-names></name><name name-style="western"><surname>Van Zandwijk</surname><given-names>N</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>F</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.</article-title>             <source>Ann Oncol</source>             <volume>15</volume>             <fpage>19</fpage>             <lpage>27</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-LasalviaPrisco1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lasalvia-Prisco</surname><given-names>E</given-names></name><name name-style="western"><surname>Garcia-Giralt</surname><given-names>E</given-names></name><name name-style="western"><surname>Vazquez</surname><given-names>J</given-names></name><name name-style="western"><surname>Aghazarian</surname><given-names>M</given-names></name><name name-style="western"><surname>Lasalvia-Galante</surname><given-names>E</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Randomized phase II clinical trial of chemo-immunotherapy in advanced non-small-cell lung cancer.</article-title>             <source>Biologics</source>             <volume>2</volume>             <fpage>555</fpage>             <lpage>561</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Lynch1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lynch</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name><name name-style="western"><surname>Dreisbach</surname><given-names>L</given-names></name><name name-style="western"><surname>McCleod</surname><given-names>M</given-names></name><name name-style="western"><surname>Heim</surname><given-names>WJ</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.</article-title>             <source>J Clin Oncol</source>             <volume>28</volume>             <fpage>911</fpage>             <lpage>917</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-OBrien1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>O'Brien</surname><given-names>ME</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaukel</surname><given-names>E</given-names></name><name name-style="western"><surname>O'Byrne</surname><given-names>K</given-names></name><name name-style="western"><surname>Pawlicki</surname><given-names>M</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.</article-title>             <source>Ann Oncol</source>             <volume>15</volume>             <fpage>906</fpage>             <lpage>914</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Pirker1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pirker</surname><given-names>R</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>JR</given-names></name><name name-style="western"><surname>Szczesna</surname><given-names>A</given-names></name><name name-style="western"><surname>von Pawel</surname><given-names>J</given-names></name><name name-style="western"><surname>Krzakowski</surname><given-names>M</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.</article-title>             <source>Lancet</source>             <volume>373</volume>             <fpage>1525</fpage>             <lpage>1531</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Ridolfi1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ridolfi</surname><given-names>L</given-names></name><name name-style="western"><surname>Bertetto</surname><given-names>O</given-names></name><name name-style="western"><surname>Santo</surname><given-names>A</given-names></name><name name-style="western"><surname>Naglieri</surname><given-names>E</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>M</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Chemotherapy with or without low-dose interleukin-2 in advanced non-small-cell lung cancer: results from a phase III randomized multicentric trial.</article-title>             <source>Int J Oncol</source>             <volume>39</volume>             <fpage>1011</fpage>             <lpage>1017</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Rosell1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rosell</surname><given-names>R</given-names></name><name name-style="western"><surname>Robinet</surname><given-names>G</given-names></name><name name-style="western"><surname>Szczesna</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramlau</surname><given-names>R</given-names></name><name name-style="western"><surname>Constenla</surname><given-names>M</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.</article-title>             <source>Ann Oncol</source>             <volume>19</volume>             <fpage>362</fpage>             <lpage>369</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Wu2">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N</given-names></name></person-group>             <year>2008</year>             <article-title>Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small-cell lung cancer.</article-title>             <source>Anticancer Res</source>             <volume>28</volume>             <fpage>3997</fpage>             <lpage>4002</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Zhong1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>R</given-names></name><name name-style="western"><surname>Teng</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H</given-names></name></person-group>             <year>2011</year>             <article-title>Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.</article-title>             <source>Cancer Immunol Immunother</source>             <volume>60</volume>             <fpage>1497</fpage>             <lpage>1502</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Begg1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name><name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name></person-group>             <year>1994</year>             <article-title>Operating characteristics of a rank correlation test for publication bias.</article-title>             <source>Biometrics</source>             <volume>50</volume>             <fpage>1088</fpage>             <lpage>1101</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Huncharek1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Huncharek</surname><given-names>M</given-names></name><name name-style="western"><surname>Geschwind</surname><given-names>JF</given-names></name><name name-style="western"><surname>Witherspoon</surname><given-names>B</given-names></name><name name-style="western"><surname>McGarry</surname><given-names>R</given-names></name><name name-style="western"><surname>Adcock</surname><given-names>D</given-names></name></person-group>             <year>2000</year>             <article-title>Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials.</article-title>             <source>J Clin Epidemiol</source>             <volume>53</volume>             <fpage>676</fpage>             <lpage>680</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Sun1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Briel</surname><given-names>M</given-names></name><name name-style="western"><surname>Walter</surname><given-names>SD</given-names></name><name name-style="western"><surname>Guyatt</surname><given-names>GH</given-names></name></person-group>             <year>2010</year>             <article-title>Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.</article-title>             <source>BMJ</source>             <volume>340</volume>             <fpage>c117</fpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Perroud1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Perroud</surname><given-names>MW</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Honma</surname><given-names>HN</given-names></name><name name-style="western"><surname>Barbeiro</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gilli</surname><given-names>SC</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>MT</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Mature autologous dendritic cell vaccines in advanced non-small-cell lung cancer: a phase I pilot study.</article-title>             <source>J Exp Clin Cancer Res</source>             <volume>30</volume>             <fpage>65</fpage>             <lpage>72</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Nemunaitis1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nemunaitis</surname><given-names>J</given-names></name><name name-style="western"><surname>Nemunaitis</surname><given-names>M</given-names></name><name name-style="western"><surname>Senzer</surname><given-names>N</given-names></name><name name-style="western"><surname>Snitz</surname><given-names>P</given-names></name><name name-style="western"><surname>Bedell</surname><given-names>C</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non-small-cell lung cancer (NSCLC) patients.</article-title>             <source>Cancer Gene Ther</source>             <volume>16</volume>             <fpage>620</fpage>             <lpage>624</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Nemunaitis2">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nemunaitis</surname><given-names>J</given-names></name><name name-style="western"><surname>Jahan</surname><given-names>T</given-names></name><name name-style="western"><surname>Ross</surname><given-names>H</given-names></name><name name-style="western"><surname>Sterman</surname><given-names>D</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.</article-title>             <source>Cancer Gene Ther</source>             <volume>13</volume>             <fpage>555</fpage>             <lpage>562</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Garcia1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>B</given-names></name><name name-style="western"><surname>Neninger</surname><given-names>E</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>A</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>I</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>R</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.</article-title>             <source>Clin Cancer Res</source>             <volume>14</volume>             <fpage>840</fpage>             <lpage>846</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Strand1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Strand</surname><given-names>L</given-names></name><name name-style="western"><surname>Morley</surname><given-names>P</given-names></name><name name-style="western"><surname>Cipolle</surname><given-names>R</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>R</given-names></name><name name-style="western"><surname>Lamsam</surname><given-names>G</given-names></name></person-group>             <year>1990</year>             <article-title>Drug-related problems: their structure and function.</article-title>             <source>Ann Pharmacother</source>             <volume>24</volume>             <fpage>1093</fpage>             <lpage>1097</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Bettauer1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bettauer</surname><given-names>RH</given-names></name></person-group>             <year>2011</year>             <article-title>Systematic review of chimpanzee use in monoclonal antibody research and drug development: 1981–2010.</article-title>             <source>ALTEX</source>             <volume>28</volume>             <fpage>103</fpage>             <lpage>116</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Limb1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Limb</surname><given-names>SL</given-names></name><name name-style="western"><surname>Starke</surname><given-names>PR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CE</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>BA</given-names></name></person-group>             <year>2007</year>             <article-title>Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.</article-title>             <source>J Allergy Clin Immunol</source>             <volume>120</volume>             <fpage>1378</fpage>             <lpage>1381</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Cox2">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>L</given-names></name><name name-style="western"><surname>Platts-Mills</surname><given-names>TA</given-names></name><name name-style="western"><surname>Finegold</surname><given-names>I</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>LB</given-names></name><name name-style="western"><surname>Simons</surname><given-names>FE</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology joint task force report on omalizumab-associated anaphylaxis.</article-title>             <source>J Allergy Clin Immunol</source>             <volume>120</volume>             <fpage>1373</fpage>             <lpage>1377</lpage>          </element-citation>
      </ref>
      <ref id="pone.0032695-Hamada1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>C</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>F</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>S</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>K</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.</article-title>             <source>J Clin Oncol</source>             <volume>23</volume>             <fpage>4999</fpage>             <lpage>5006</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>